vTv Therapeutics Inc. VTVT
Updated: 9 Aug 2026
No signal published yet
We already track vTv Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow vTv Therapeutics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow vTv Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, vTv Therapeutics reported its second quarter 2026 financial results, highlighting a cash position of $86.6 million. The company announced that enrollment in its Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes is expected to complete in the third quarter of 2026. Furthermore, vTv plans to initiate a Phase 2a trial evaluating cadisegliatin in hybrid closed-loop systems before year-end 2026.
What Firelda Watch includes for vTv Therapeutics Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow vTv Therapeutics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow vTv Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more